Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Recruiting

• Conditions: Takayasu Arteritis With Pulmonary Artery Involvement; Percutaneous Transluminal Pulmonary Angioplasty; PAH Targeted Medication

• Registration Number: NCT05388682
• Lead Sponsor: Chinese Pulmonary Vascular Disease Research Group

Brief Summary

1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement

2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

Detailed Description

At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

Study Timeline

• Study Start: 2014-01-19
• Study First Submitted: 2022-05-19
• Study First Submitted QC: 2022-05-19
• Study First Posted: 2022-05-24
• Status Verified: 2023-01
• Last Update Submitted: 2023-12-14
• Last Update Posted: 2023-12-20
• Primary Completion: 2042-12-31
• Study Completion: 2042-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• patients diagnosed with Takayasu arteries with pulmonary arteries involvement

Exclusion Criteria

• Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mean pulmonary arterial pressure change	2014/1/1-2042/12/31	change of mean pulmonary arterial pressure after treatment
pulmonary vascular resistance change	2014/1/1-2042/12/31	chagne of pulmonary vascular resistance after treatment
peak VO2 change	2014/1/1-2042/12/31	change of peak oxygen consumption after treatment
NT-proBNP change	2014/1/1-2042/12/31	change of NT-proBNP after treatment
all cause death	2014/1/1-2042/12/31	all cause death
6MWD change	2014/1/1-2042/12/31	change of six minute walk distance after treatment
CI change	2014/1/1-2042/12/31	change of cardiac index after treatment
RV/LV change	2014/1/1-2042/12/31	change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment

Trial Locations

Locations (1)

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College; 🇨🇳 Beijing, China